Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions. It also offers PROTAC/molecular glue services, including protein preparation and ternary complex structure determination, screening for molecule glues and novel E3 ligase ligands, PROTAC ternary complex kinetics, PROTAC degradation assays and ternary complex assays, PROTAC molecule design and synthesis, ADME & PK/PD studies of PROTAC molecules, and computer aided PROTAC design solutions; and XDC platforms, such as XDC conjugation and quality study, XDC chemistry research and development, and XDC functional studies. In addition, the company offers contract development and manufacturing services comprising integrated services for small molecule active pharmaceutical ingredients, formulation development and production services, and pharmaceutical analysis services, as well as CMC filing, global filing registration support, and other services.